Physician profile
Michael Alan Garone
NPI 1811304009
$4,715.09
in general payments reported to CMS, 2019-2025
26 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $640 · 2021: $673 · 2022: $572 · 2023: $464 · 2024: $542 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.18 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,376.74 | 2019-2025 | |
| Lilly USA, LLC | $436.21 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $400.86 | 2019-2022 | |
| Biowound Solutions, INC. | $381.05 | 2025 | Bio-Connekt |
| Genzyme Corporation | $339.66 | 2019-2025 | |
| Galderma Laboratories, L.P. | $202.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $202.07 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $200.77 | 2020-2024 | Ilumya, Blu-U, Odomzo |
| Janssen Biotech, INC. | $158.72 | 2019-2025 | Tremfya |
| Organogenesis INC. | $156.63 | 2021-2025 | Novachor, Via Matrix, Cygnus Dual |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.74 | 2019-2024 | Siliq |
| Regeneron Healthcare Solutions, INC. | $118.69 | 2019-2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $104.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.83 | 2020-2021 | |
| Allergan, INC. | $86.29 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $53.88 | 2019-2021 | |
| Amgen INC. | $48.78 | 2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $48.73 | 2022-2025 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $41.36 | 2019 | |
| Celgene Corporation | $23.86 | 2019 | |
| Leo Pharma INC. | $20.39 | 2023 | Adbry |
| Daiichi Sankyo INC. | $19.53 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.04 | 2022 | |
| Strata Skin Sciences, INC. | $17.39 | 2024 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.53 | 2024 | Cyltezo |
| Dermira, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Garone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.